Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients with Myelodysplastic Syndromes (MDS) (PR Newswire)
Posted on December 9, 2007 at 5:23 am in Online Trading
Pharmion Corporation today announced complete results from a Phase 3 multi-center, international, randomized study of Vidaza® in the treatment of patients with higher-risk myelodysplastic syndromes demonstrating that Vidaza provides a significant survival benefit compared to conventional care regimens in higher-risk MDS patients.
More: continued here
